OABI Key Statistics, Chart & Performance
The current stock price of OABI is 1.885 USD. In the past month the price decreased by -5.64%. In the past year, price decreased by -46.51%.
OABI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.7 | 233.13B | ||
| DHR | DANAHER CORP | 30.41 | 165.61B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 199.99 | 60.77B | ||
| A | AGILENT TECHNOLOGIES INC | 26.43 | 41.81B | ||
| IQV | IQVIA HOLDINGS INC | 21 | 41.59B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.17 | 30.06B | ||
| WAT | WATERS CORP | 31.41 | 23.75B | ||
| ILMN | ILLUMINA INC | 34.44 | 22.94B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.7 | 20.19B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.3 | 17.04B | ||
| TEM | TEMPUS AI INC | N/A | 12.61B | ||
| RVTY | REVVITY INC | 21.45 | 11.65B |
Related stock screener links
About OABI
Company Profile
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 114 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Company Info
OMNIAB INC
5980 Horton Street, Suite 600
Emeryville CALIFORNIA US
Employees: 114
Phone: 15102507800
OMNIAB INC / OABI FAQ
What does OMNIAB INC do?
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 114 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Can you provide the latest stock price for OMNIAB INC?
The current stock price of OABI is 1.885 USD. The price increased by 2.45% in the last trading session.
Does OMNIAB INC pay dividends?
OABI does not pay a dividend.
What is the ChartMill rating of OMNIAB INC stock?
OABI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is OMNIAB INC (OABI) expected to grow?
The Revenue of OMNIAB INC (OABI) is expected to decline by -25.22% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for OABI stock?
OMNIAB INC (OABI) currently has 114 employees.
OABI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OABI. When comparing the yearly performance of all stocks, OABI is a bad performer in the overall market: 83.78% of all stocks are doing better.
OABI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OABI. OABI has a great financial health rating, but its profitability evaluates not so good.
OABI Financial Highlights
Over the last trailing twelve months OABI reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 6.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.54% | ||
| ROE | -22.92% | ||
| Debt/Equity | 0 |
OABI Forecast & Estimates
13 analysts have analysed OABI and the average price target is 7.48 USD. This implies a price increase of 296.82% is expected in the next year compared to the current price of 1.885.
For the next year, analysts expect an EPS growth of 7.71% and a revenue growth -25.22% for OABI